Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by MAIA Biotechnology, Inc.

< Previous 1 2 3 Next >
MAIA Biotechnology Reveals New Data Showing THIO’s Potent Anticancer Activity in Aggressive Pediatric Brain Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed Patients
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Potent Anticancer Activity of THIO in Gliomas
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Share Repurchase Program
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Updates on Preliminary Survival Data for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Updates in Enrollment in Phase II Clinical Trial: THIO-101 Has Enrolled 29 Patients
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Files Second Patent For New Telomere-Targeting Molecules Program
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports First Quarter 2023 Financial Results and Provides Corporate Update
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology, Inc. Announces Closing of Public Offering
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology, Inc. Announces Pricing of Public Offering
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Preliminary Survival Data in Part A of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Excellent Efficacy of THIO in Liver Cancer Models
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Present at AACR Annual Meeting 2023
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Positive Topline Data from Part A Safety Lead-In of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Full Year 2022 Financial Results and Provides Corporate Update
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces No Exposure to Silicon Valley Bank
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Doses First Patients in Europe in Ongoing Phase 2 Trial (THIO-101) Evaluating THIO for Non-Small Cell Lung Cancer Treatment
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
ADDING MULTIMEDIA: MAIA Biotechnology’s Telomere-targeting Agent THIO, in Combination With Checkpoint Inhibitor Immune Therapies Atezolizumab (anti-PD-L1) or Pembrolizumab (anti-PD-1), Demonstrated Significantly Greater Tumor Inhibition
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Advances New Telomere-Targeting Molecule Program
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Participate in Four Upcoming Investor Conferences
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Expands Phase 2 THIO-101 Trial to Europe
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Establishment of Rule 10b5-1 Trading Plan
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Presents Preclinical Data at SITC Annual Meeting Validating Efficacy of THIO in Treating Hepatocellular Carcinoma
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Participate in ThinkEquity Conference
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.